Interestingly, HCC patients with high expression of HMGB2, MYBL2, HMGA1, FOXM1, TCF19, CENPA or E2F1 exhibited higher resistance to trametinib (Fig. 7E). This evidence concerns the gene E2F1 and hepatocellular carcinoma.